tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

DNTH Stock Latest News

Dianthus Therapeutics’ DNTH103: A Promising Complement Inhibitor with Upcoming Catalysts
RatingsDianthus Therapeutics’ DNTH103: A Promising Complement Inhibitor with Upcoming Catalysts
4d ago
DNTH
Dianthus initiated with an Outperform at William Blair
PremiumThe Fly
Dianthus initiated with an Outperform at William Blair
16d ago
DNTH
Dianthus Therapeutics: Promising Prospects in Autoimmune Complement Inhibitor Market with DNTH103 Advancements
PremiumRatings
Dianthus Therapeutics: Promising Prospects in Autoimmune Complement Inhibitor Market with DNTH103 Advancements
16d ago
DNTH
Optimistic Buy Rating for Dianthus Therapeutics Amidst Promising C1s Inhibition Developments
PremiumRatings
Optimistic Buy Rating for Dianthus Therapeutics Amidst Promising C1s Inhibition Developments
17d ago
DNTH
Buy Rating for Dianthus Therapeutics: Promising Growth Potential of DNTH103 in Neuromuscular Disease Treatment
PremiumRatings
Buy Rating for Dianthus Therapeutics: Promising Growth Potential of DNTH103 in Neuromuscular Disease Treatment
29d ago
DNTH
Dianthus Therapeutics Announces Board Changes and Elections
PremiumCompany AnnouncementsDianthus Therapeutics Announces Board Changes and Elections
2M ago
8K
DNTH
Buy Rating Affirmed for Dianthus Therapeutics: Promising Clinical Potential of DNTH103 in CIDP Treatment
Premium
Ratings
Buy Rating Affirmed for Dianthus Therapeutics: Promising Clinical Potential of DNTH103 in CIDP Treatment
2M ago
DNTH
Dianthus Therapeutics: Strong Financial Position and Promising Clinical Developments Justify Buy Rating
Premium
Ratings
Dianthus Therapeutics: Strong Financial Position and Promising Clinical Developments Justify Buy Rating
2M ago
DNTH
Dianthus price target lowered to $50 from $58 at Baird
PremiumThe Fly
Dianthus price target lowered to $50 from $58 at Baird
2M ago
DNTH
Promising Developments and Strong Financials Support Buy Rating for Dianthus Therapeutics
PremiumRatings
Promising Developments and Strong Financials Support Buy Rating for Dianthus Therapeutics
2M ago
DNTH
Dianthus Therapeutics Reports Increased R&D Expenses
PremiumCompany Announcements
Dianthus Therapeutics Reports Increased R&D Expenses
2M ago
DNTH
Promising Outlook for Dianthus Therapeutics: Buy Rating Backed by Clinical Progress and Financial Stability
PremiumRatings
Promising Outlook for Dianthus Therapeutics: Buy Rating Backed by Clinical Progress and Financial Stability
2M ago
DNTH
Dianthus completes enrollment for Phase 2 MaGic Trial of DNTH103
PremiumThe FlyDianthus completes enrollment for Phase 2 MaGic Trial of DNTH103
2M ago
DNTH
Short Report: Bears bite into solar with higher exposure to Sunrun, SolarEdge
Premium
The Fly
Short Report: Bears bite into solar with higher exposure to Sunrun, SolarEdge
3M ago
PCT
RUN
Short Report: Bears focus on crypto space, boost bets on CleanSpark, Mara
Premium
The Fly
Short Report: Bears focus on crypto space, boost bets on CleanSpark, Mara
4M ago
CELH
CLSK
Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress
PremiumCompany Announcements
Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress
4M ago
DNTH
Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating
PremiumRatings
Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating
4M ago
DNTH
Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress
PremiumRatings
Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress
4M ago
DNTH
Dianthus Therapeutics: Promising Growth Potential with Innovative DNTH103 and Strong Financial Position
PremiumRatings
Dianthus Therapeutics: Promising Growth Potential with Innovative DNTH103 and Strong Financial Position
4M ago
DNTH
Dianthus reports Q4 EPS (81c), consensus (76c)
PremiumThe FlyDianthus reports Q4 EPS (81c), consensus (76c)
4M ago
DNTH
Dianthus Therapeutics Appoints Sujay Kango to Board
Premium
Company Announcements
Dianthus Therapeutics Appoints Sujay Kango to Board
4M ago
8K
DNTH
Dianthus appoints King as Chief Commercial Officer
Premium
The Fly
Dianthus appoints King as Chief Commercial Officer
4M ago
DNTH

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >